Tau hyperphosphorylation and conformational changes in the brain parenchyma start around seven months. Tangle-like pathology is mainly observed in the brain stem and spinal cord, and to a lesser ...

TauRx was an early proponent of the notion that tau protein could be a legitimate drug target in Alzheimer's, since it was taken up by a lot of larger companies, including Roche/UCB, Johnson ...

Investors in TauRx Pharma have exercised warrants worth around $119 million, adding to the biotech's financial resources as it prepares regulatory filings for tau-targeting Alzheimer's drug ...